Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

PCTs doubtful over arthritis drug after 'thumbs down' from NICE

  • Comment

Doubts have been raised over whether the ‘smart’ drug Tocilizumab, which treats rheumatoid arthritis, will be made available on the NHS.

Trials have shown that the drug can significantly improve the lives of patients who can no longer benefit from other therapies, but at a cost of £9,300 per patient per year, the drug may be too expensive for the NHS.

The decision to pay for the drug rests with the regional PCTs, but as NICE has given a preliminary “thumbs down” rating, they are unlikely to choose to fund it.

The decision has been described as “extremely bad news” by the National Rheumatoid Arthritis Society, which supports sufferers of the disease, however final guidance will not be produced by NICE until next year.

A possible outcome might be that the drug’s manufacturer, pharmaceutical giants Roche, strikes a deal to share the cost burden with the NHS.

Tocilizumab works by targetting a key signalling molecule that underpins many inflammatory processes.

Meanwhile, the Scottish Medicines Consortium is expected to issue separate guidance for Tocilizumab north of the border.


Should PCTs fund Tocilizumab?

View poll results
  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs